TY - JOUR
T1 - Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test
AU - Heggestad, Jacob T.
AU - Kinnamon, David S.
AU - Olson, Lyra B.
AU - Liu, Jason
AU - Kelly, Garrett
AU - Wall, Simone A.
AU - Oshabaheebwa, Solomon
AU - Quinn, Zachary
AU - Fontes, Cassio M.
AU - Joh, Daniel Y.
AU - Hucknall, Angus M.
AU - Pieper, Carl
AU - Anderson, Jack G.
AU - Naqvi, Ibtehaj A.
AU - Chen, Lingye
AU - Que, Loretta G.
AU - Oguin, Thomas
AU - Nair, Smita K.
AU - Sullenger, Bruce A.
AU - Woods, Christopher W.
AU - Burke, Thomas W.
AU - Sempowski, Gregory D.
AU - Kraft, Bryan D.
AU - Chilkoti, Ashutosh
N1 - Publisher Copyright:
© 2021 American Association for the Advancement of Science. All rights reserved.
PY - 2021/6
Y1 - 2021/6
N2 - Highly sensitive, specific, and point-of-care (POC) serological assays are an essential tool to manage coronavirus disease 2019 (COVID-19). Here, we report on a microfluidic POC test that can profile the antibody response against multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens-spike S1 (S1), nucleocapsid (N), and the receptor binding domain (RBD)-simultaneously from 60 l of blood, plasma, or serum. We assessed the levels of antibodies in plasma samples from 31 individuals (with longitudinal sampling) with severe COVID-19, 41 healthy individuals, and 18 individuals with seasonal coronavirus infections. This POC assay achieved high sensitivity and specificity, tracked seroconversion, and showed good concordance with a live virus microneutralization assay. We can also detect a prognostic biomarker of severity, IP-10 (interferon-induced protein 10), on the same chip. Because our test requires minimal user intervention and is read by a handheld detector, it can be globally deployed to combat COVID-19.
AB - Highly sensitive, specific, and point-of-care (POC) serological assays are an essential tool to manage coronavirus disease 2019 (COVID-19). Here, we report on a microfluidic POC test that can profile the antibody response against multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens-spike S1 (S1), nucleocapsid (N), and the receptor binding domain (RBD)-simultaneously from 60 l of blood, plasma, or serum. We assessed the levels of antibodies in plasma samples from 31 individuals (with longitudinal sampling) with severe COVID-19, 41 healthy individuals, and 18 individuals with seasonal coronavirus infections. This POC assay achieved high sensitivity and specificity, tracked seroconversion, and showed good concordance with a live virus microneutralization assay. We can also detect a prognostic biomarker of severity, IP-10 (interferon-induced protein 10), on the same chip. Because our test requires minimal user intervention and is read by a handheld detector, it can be globally deployed to combat COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85108818883&partnerID=8YFLogxK
U2 - 10.1126/sciadv.abg4901
DO - 10.1126/sciadv.abg4901
M3 - Article
C2 - 34172447
AN - SCOPUS:85108818883
SN - 2375-2548
VL - 7
JO - Science Advances
JF - Science Advances
IS - 26
M1 - eabg4901
ER -